A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: The Glucontrol study

Jean Charles Preiser, Philippe Devos, Sergio Ruiz-Santana, Christian Mélot, Djillali Annane, Johan Groeneveld, Gaetano Iapichino, Xavier Leverve, Gérard Nitenberg, Pierre Singer, Jan Wernerman, Michael Joannidis, Adela Stecher, René Chioléro

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: An optimal target for glucose control in ICU patients remains unclear. This prospective randomized controlled trial compared the effects on ICU mortality of intensive insulin therapy (IIT) with an intermediate glucose control. Methods: Adult patients admitted to the 21 participating medico-surgical ICUs were randomized to group 1 (target BG 7.8-10.0 mmol/L) or to group 2 (target BG 4.4-6.1 mmol/L). Results: While the required sample size was 1,750 per group, the trial was stopped early due to a high rate of unintended protocol violations. From 1,101 admissions, the outcomes of 542 patients assigned to group 1 and 536 of group 2 were analysed. The groups were well balanced. BG levels averaged in group 1 8.0 mmol/L (IQR 7.1-9.0) (median of all values) and 7.7 mmol/L (IQR 6.7-8.8) (median of morning BG) versus 6.5 mmol/L (IQR 6.0-7.2) and 6.1 mmol/L (IQR 5.5-6.8) for group 2 (p < 0.0001 for both comparisons). The percentage of patients treated with insulin averaged 66.2 and 96.3%, respectively. Proportion of time spent in target BG was similar, averaging 39.5% and 45.1% (median (IQR) 34.3 (18.5-50.0) and 39.3 (26.2-53.6)%) in the groups 1 and 2, respectively. The rate of hypoglycaemia was higher in the group 2 (8.7%) than in group 1 (2.7%, p < 0.0001). ICU mortality was similar in the two groups (15.3 vs. 17.2%). Conclusions: In this prematurely stopped and therefore underpowered study, there was a lack of clinical benefit of intensive insulin therapy (target 4.4-6.1 mmol/L), associated with an increased incidence of hypoglycaemia, as compared to a 7.8-10.0 mmol/L target. (ClinicalTrials.gov # NCT00107601, EUDRA-CT Number: 200400391440).

Original languageEnglish
Pages (from-to)1738-1748
Number of pages11
JournalIntensive Care Medicine
Volume35
Issue number10
DOIs
StatePublished - Oct 2009
Externally publishedYes

Keywords

  • Critical illness
  • Hypoglycaemia
  • Insulin resistance
  • Insulin therapy
  • Stress hyperglycaemia

Fingerprint

Dive into the research topics of 'A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: The Glucontrol study'. Together they form a unique fingerprint.

Cite this